Abstract
Grade 2 NET liver metastases have less durable PFS than low-grade tumors following embolotherapy (12 months vs. 18 months, Chen 2017). Capecitabine-temozolomide (CapTem) is an effective regimen in NETs and both drugs are radiosensitizers. A feasibility study of integrated CapTem and Y-90 transarterial radioembolization (TARE) demonstrated tolerability with expected additive toxicities and encouraging ORR and PFS (Soulen 2018). This study expands that report to a larger cohort with oncologic follow-up.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
